Glitazones in the treatment of cardiovascular risk factors.
This review focuses on the recent advances on the role of the nuclear receptor peroxisome proliferator-activated receptor gamma in the modulation of vascular lipid homeostasis and the inflammatory response and the potential role of these activities in the modulation of metabolic and cardiovascular disease.
Bouhlel
Mohamed Amine
MA
Institut Pasteur de Lille, Lille, F-59019 France.
Chinetti-Gbaguidi
Giulia
G
Staels
Bart
B
D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000517:prevention & control*; D002784:Cholesterol / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists / Q000378:metabolism; D012307:Risk Factors; D045162:Thiazolidinediones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D047495:PPAR gamma; D045162:Thiazolidinediones; D002784:Cholesterol